Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.92 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.92 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.92 |
| ▸ | TP53 | P04637 | 1/20 | 0.92 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.92 |
| ▸ | TSHR | P16473 | 1/20 | 0.92 |
| ▸ | CA12 | O43570 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CA4 | P22748 | 2/20 | 0.62 |
| ▸ | CA6 | P23280 | 2/20 | 0.62 |
| ▸ | CA5A | P35218 | 2/20 | 0.62 |
| ▸ | CA7 | P43166 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.62 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.62 |
| ▸ | HTR6 | P50406 | 3/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77781 | 0.96 | F2 (1.00) | F2TMPRSS4CYP1A2TP53CYP2D6 | |
| Hydrochloric Acid SCHEMBL6425431 | 0.94 | F2 (1.00) | F2TMPRSS4CYP1A2TP53CYP2D6 | |
| Hydrochloric Acid SCHEMBL25973 | 0.94 | F2 (1.00) | F2TMPRSS4CYP1A2TP53CYP2D6 | |
| Hydrochloric Acid SCHEMBL28825226 | 0.92 | F2 (0.96) | F2TMPRSS4CYP1A2TP53CYP2D6 | |
| Hypochlorous Acid SCHEMBL17004810 | 0.90 | F2 (0.89) | F2TMPRSS4CYP1A2TP53CYP2D6 | |
| SCHEMBL31631413 | 0.80 | F2 (0.71) | F2TMPRSS4CYP1A2TP53CYP2D6 | |
| SCHEMBL6680951 | 0.79 | HTR6 (0.84) | F2TMPRSS4CYP1A2TP53CYP2D6 | |
| Benzamidine SCHEMBL3427811 | 0.78 | F2 (0.66) | F2TMPRSS4CYP1A2TP53CYP2D6 | |
| Hydrochloric Acid SCHEMBL21199324 | 0.77 | F2 (0.70) | F2TMPRSS4CYP1A2TP53CYP2D6 | |
| SCHEMBL142107 | 0.77 | CA2 (1.00) | F2TMPRSS4CYP1A2TP53CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112400024-B | Device and system for gastrointestinal microbiome detection and processing | 比奥拉治疗股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230408504-A1 | ANTIBODY BARCODED BEADS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-12-21 | — | — | US | disclosed |
| EP-4252629-A2 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | Biora Therapeutics, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-4244378-A1 | METHOD FOR DETECTING NUCLEIC ACIDS IN A BIOLOGICAL SAMPLE | Innovative Diagnostics (FR) | 2023-09-20 | — | — | EP | disclosed |
| EP-3551046-B1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | BIORA THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230190662-A1 | Efficacy of a Gastro-Retentive Bile Acid Sequestrant Dosage Form | IRONWOOD PHARMACEUTICALS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-11547301-B2 | Methods for collecting and testing bacteria containing samples from within the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220370367-A1 | Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid Sequestrant | IRONWOOD PHARMACEUTICALS INC (US) | 2022-11-24 | — | — | US | disclosed |
| CN-114767646-A | Effects of gastric retentive bile acid sequestrant formulation | 铁木医药有限公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2022101583-A1 | METHOD FOR DETECTING NUCLEIC ACIDS IN A BIOLOGICAL SAMPLE | INNOVATIVE DIAGNOSTICS GENETICS (FR) | 2022-05-19 | — | — | WO | disclosed |
| WO-2012027331-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLIC SYNDROME AND RELATED DISEASES AND DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110129433-A1 | Compositions and Methods for Treating or Preventing Gastrointestinal Disorders and GERD-Related Respiratory Disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20100179235-A1 | COMPOSITIONS COMPRISING BILE ACID SEQUESTRANTS FOR TREATING ESOPHAGEAL DISORDERS | IRONWOOD PHARMACEUTICALS (US) | 2010-07-15 | — | — | US | disclosed |
| WO-2009158625-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GASTROINTESTINAL DISORDERS AND GERD-RELATED RESPIRATORY DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| EP-2124884-A2 | COMPOSITIONS COMPRISING BILE ACID SEQUESTRANTS FOR TREATING ESOPHAGEAL DISORDERS | Ironwood Pharmaceuticals, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008080092-A2 | COMPOSITIONS COMPRISING BILE ACID SEQUESTRANTS FOR TREATING ESOPHAGEAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080025966-A1 | Methods And Compositions For The Treatment Of Gastrointestinal disorders | IRONWOOD PHARMACEUTICALS, INC. | 2008-01-31 | — | — | US | disclosed |
| WO-2006102069-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2005074575-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11547301-B2 | Methods for collecting and testing bacteria containing samples from within the gastrointestinal tract | SI, VIP, MLN | SLC6A2 3948/4885F2 717/4885TMPRSS4 694/4885 |
| US-20110129433-A1 | Compositions and Methods for Treating or Preventing Gastrointestinal Disorders and GERD-Related Respiratory Disorders | HRH2, GABRB1, GABRB3 | SLC6A2 969/4885F2 2060/4885TMPRSS4 620/4885 |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | PTGIS, PTGIR, GRPR | SLC6A2 2270/4885F2 2634/4885TMPRSS4 4163/4885 |
| US-20080025966-A1 | Methods And Compositions For The Treatment Of Gastrointestinal disorders | SI, CMA1, CTRB1 | SLC6A2 3759/4885F2 1194/4885TMPRSS4 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.